Detalles de la búsqueda
1.
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.
Arthritis Res Ther
; 24(1): 161, 2022 06 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35773713
Resultados
1 -
1
de 1
1
Próxima >
>>